In his weekly clinical update, Dr. Griffin apprises us about the first case of highly pathogenic influenza in Canda, children dying of influenza infection and novel genetic reassortments of the virus, the Marburg virus outbreak in Rwanda, number of mpox infections, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, how scientific mistrust has affected COVID-19 vaccine administration, resolution of the FDA hold on Novovax’s combination influenza and COVID vaccine, where to find PEMGARDA, how Paxlovid SAVES you money, when to use steroids to treat COVID-19 and how trace amounts of cytokines elicted during SARS-CoV-2 infection negatively impact cardiac function.
Click arrow to play
Download TWiV 1166 (28 MB .mp3, 46 min)
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Bird flu flew into British Columbia Canada (Global News Canada)
- H5N1 in British Columbia (CIDRAP)
- Highly Pathogenic Avian Influenza flies commercial and domestic (USDA)
- Countdown till the end of Marburg outbreak (WHO Rwanda)
- First kid’s death due to flu (CIDRAP)
- Influenza weekly surveillance report: clift notes (CDC FluView)
- H5N1 novel reassortments in migratory birds in China (Emerging Infectious Diseases)
- Serologic evidence of recent infection with highly pathogenic avian influenza A (MMWR)
- Seriously? 50,000 mpox cases in African outbreak (CIDRAP)
- Respiratory virus activity (CDC Respiratory Illnesses)
- COVID-19 deaths (CDC)
- COVID-19 national and regional trends (CDC)
- Waste water scan for 11 pathogens (WastewaterSCan)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- Science trust: behind COVID 19 vaccine acceptance (Vaccine X)
- Vaccine mistrust levels are not budging (Healthday)
- FDA clinical hold lifted on Novavax’s combination COVID-flu vaccine(Reuters)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- Fusion center near you….if in NY (Prime Fusions)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir (CMI: Clinical Microbiology and Infection)
- Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (CID)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What to do when sick with a respiratory virus (CDC)
- When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Secondary bacterial infection follows COVID-19 (Nature Communications)
- Daniel Griffin’s evidence based medical practices for long COVID (OFID)
- Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function (Nature Medicine)
- Letters read on TWiV 1166
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1166: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.
That’s quite unfortunate to hear about Futures in Biotech, although kudos to you all for starting the new podcast network.
Do you plan to do any promotion of an #asv2012 hashtag for the meeting in Madison this year? I remember some limited tweeting from Minneapolis last year (in between melting into the sidewalk) but I think TWiV would be a great way to promote it ahead of time, along with using it when you tweet about the TWiV episode to be recorded there. After the discomfort with livetweeting the morning sessions last year it may not be encouraged, but I think ASV could be moving faster in the social media realm.
As you said on twitter, there was a specially designed app for ASM this year, and I know Society for Neuroscience has one too. ASV as far as I can tell doesn’t even have a twitter account and only the barest of Facebooks. With all of the focus on H5N1 (loved the discussion) this seems like the perfect time to expand ASV’s reach on the Internet.
Maybe I’ll apply to run their social media presence once I finish my PhD. Someday.
Colm, I do plan to livetweet some of of the ASV sessions, or at least until someone tells me to stop. I’ll use the hashtag #ASV12. Sadly, I forgot to announce it on TWiV 191 and 192 won’t be heard in time for most, although I’ll try to remember to mention it. Maybe I’ll release 192 a bit earlier.
ASV doesn’t have much of any presence except to run the annual meeting, which is their main charge. I am on the education committee and could prod them to increase their social media presence.
I love the title. 🙂
I wonder how many labs are synthesizing these mutations and putting them in their strains right now?
when you look at the sequences, then it becomes clear that F6
is not derived from F2. So, either it got a mixed population
or it did get it from another ferret (not its designed
contact-ferret) or contamination. page 1539,2nd column, last paragraph
all these mutations, except the initial 5,
look rather arbitrary and I doubt they would be reproduced
if they ran exactly the same experiment again.